研报掘金丨华安证券：维持众生药业“买入”评级，创新转型进入收获期

Group 1 - The core viewpoint of the report is that Zhongsheng Pharmaceutical's RAY1225 has successfully landed domestic commercialization cooperation, marking a significant phase in its innovative transformation [1] - The company will receive a double-digit sales commission on the net sales of licensed products after they are launched domestically, indicating a strong potential for revenue growth [1] - The report highlights the approval and gradual market penetration of the innovative flu drug, Anladiwei tablets, and emphasizes the promising results of the long-acting GLP-1 RAY1225 injection in Phase II clinical trials, showcasing good efficacy and safety [1] Group 2 - The report suggests continuous monitoring of the product's subsequent development and overseas rights authorization after domestic commercialization [1] - The previous profit forecast is maintained, and the investment rating remains at "Buy," reflecting confidence in the company's future performance [1]